Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03495102 · ClinicalTrials.gov registry record · Phase 3
A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,842
- Enrollment target
NCT03495102: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT03495102 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,842 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (139% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03495102, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,842 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of investigational doses of once weekly dulaglutide when added to metformin in participants with type 2 diabetes with inadequate blood sugar control.
Primary Outcome
HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. The Least Squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included the independent variables:Baseline + Pooled Country + Treatment + Time + Treatment\*Time (Type III sum of squares).
Interventions
- DRUG Dulaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,842 participants |
| Start Date | 2018-04-05 |
| Est. Completion | 2019-10-10 |
| Phase | Phase 3 |
What the finished NCT03495102 record still lists
NCT03495102 is an interventional study that assigns participants to a tested intervention. Its 1,842 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (139% higher).
The record links to 0 conditions, and to 1 intervention - of which Dulaglutide is the first listed.
NCT03495102 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03495102 about?
NCT03495102 is a clinical study titled "A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes". The purpose of this study is to evaluate the efficacy and safety of investigational doses of once weekly dulaglutide when added to metformin in participants with type 2 diabetes with inadequate blood sugar control.
What is the current status of trial NCT03495102?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,842 participants. The study started on 2018-04-05. Estimated completion is 2019-10-10.
What interventions are being tested in trial NCT03495102?
The interventions under investigation include: Dulaglutide (DRUG).
Who is sponsoring clinical trial NCT03495102?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03495102's enrollment target sits among peer trials
1,842 114th of 2000 higher than 1,887 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06740630 · 1,840 participants · Phase 3
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
- NCT07104240 · 1,836 participants · NA
A Vaccine Promotion Package (TweenVax) to Improve Adolescent HPV Vaccination, TweenVax Trial
- NCT06465810 · 1,850 participants
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
- NCT06580080 · 1,850 participants · NA
Evaluation of Are You Ready?
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI